Search the Newsreel

ePlus inc (PLUS) Valuation: PE, PB & Fair Value Analysis

ePlus inc (PLUS) currently has a valuation score of 8.58, placing it 200th out of 485 companies in the Software & IT Services industry. Its P/E ratio is 18.42, which is significantly below its recent high and above its recent low. Other key valuation …

Replimune Group Number of Employees 2026 | Employee Count & Headcount Data

Replimune Group, a Pharmaceuticals company founded in 2015 and headquartered in Woburn, Massachusetts, had approximately 469 employees worldwide as of March 2026, representing a 35.9% growth from 2023 but a 1.2% decline year-over-year. The company's workforce is concentrated in the United States, followed by …

Repligen Corp Q2 2026: Revenue $204.1M, EPS $0.09— 10-Q Summary

Repligen Corp (RGEN) reported its second-quarter 2026 results, with revenue increasing by 11.9% year-over-year to $204.1 million. Despite the revenue growth, net income declined to $5 million, and diluted earnings per share fell to $0.09 from $0.26 in the prior-year quarter. The company also …

REPL: Replimune Group Inc Latest Stock Price, Analysis, News and Trading Ideas

This article provides a current overview of Replimune Group Inc. (REPL) stock, including its latest price, market performance, and financial fundamentals. It highlights recent news regarding a significant stock drop due to FDA documents and ongoing securities fraud investigations, alongside details on upcoming earnings …

REPL INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud

NEW YORK, July 29, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Replimune Group Inc. (“Replimune” or the “Company”) (NASDAQ: REPL). The investigation concerns whether the Company and/or members of its senior management may have violated …

Rockefeller Capital (PLUS) schedules ePlus stock sales from prior awards

Rockefeller Capital Management has filed a Form 144 notice indicating its intent to sell ePlus (EPLUS) common stock. The filing lists multiple 5,000-share stock awards received as compensation, with award dates ranging from June 2024 to June 2025. This regulatory filing aims to ensure …

EPLUS (PLUS) holder schedules 1,935-share sale valued at $181,905.20

A stockholder associated with Darren S Raiguel plans to sell 1,935 shares of EPLUS (PLUS) common stock through Rockefeller Capital Management on or after July 29, 2026. The planned sale is valued at $181,905.20 and represents a small fraction of the 26,392,561 shares outstanding. …

BioLife $1.5B buyout to expand Repligen Corporation (NASDAQ: RGEN) platform

Repligen Corporation reported strong Q2 2026 revenue of $204.1 million, an 11.9% increase from Q2 2025, with first-half revenue reaching $398.4 million. The company announced a definitive agreement to acquire BioLife Solutions for approximately $1.5 billion, aiming to expand its cell therapy capabilities. This …

Repligen Beats Q2 Earnings Estimates, Raises 2026 View, Stock Up

Repligen (RGEN) reported strong second-quarter 202

Why Repligen (RGEN) Stock Is Up Today

Shares of Repligen Corporation (NASDAQ: RGEN) rose significantly after the biopharma manufacturing company reported strong second-quarter results, beating analyst expectations for both adjusted earnings and revenue. The company also raised its full-year guidance, signaling confidence in its continued performance. This positive news contrasts with …

ePlus stock hits 52-week high at 93.99 USD By Investing.com

ePlus Inc. shares reached a 52-week high of $93.99, marking a 36.73% return over the past year. Despite trading near its high, InvestingPro's Fair Value analysis suggests the stock might be overvalued, though its PEG ratio of 0.66 indicates an attractive valuation relative to …

Repligen Earnings: Excellent Profit Margins, China Recovery Underway

Repligen Offers Differentiated Solutions as a Leading Bioprocessing Supplier

Repligen is highlighted as a leading provider of bioprocessing solutions for biologic drug manufacturers. The company offers a range of advanced systems including filtration, fluid management, chromatography columns, and process analytics. Despite its relatively small size, Repligen is noted for its innovation and record …

Canaccord reiterates Hold on Repligen stock, keeps $145 target

Canaccord Genuity has reiterated a Hold rating on Repligen Corp. (NASDAQ:RGEN) and maintained its $145 price target, believing the shares are fairly valued. The bioprocessing company exceeded analyst expectations for its second-quarter 2026 results, reporting strong revenue growth across all franchises and raising its …

Replimune Group, Inc. SEC Filing (Jul 28, 2026)

This article announces an SEC filing (type ARS) by Replimune Group, Inc. (REPL) on July 28, 2026. The filing was accepted by the SEC on July 28, 2026, at 06:26 PM and is available as a PDF document. StockTitan provides additional context, including filing …

Replimune tanks on FDA concerns about its skin cancer therapy

Replimune Group Inc. (NASDAQ: REPL) saw its stock slide by over 37% after the FDA released documents raising serious questions about its skin cancer treatment, RP1, ahead of an advisory committee meeting. The FDA deemed the data package "not interpretable" due to the single-arm …

Seplat Energy boosts profits, cuts debt and raises dividends amid JV stake sale and leadership transition

Repligen Reports Second Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance

Repligen Corporation reported strong second-quarter 2026 financial results, with revenue reaching $204 million, marking a 12% year-over-year increase. The company also announced a definitive agreement to acquire BioLife Solutions, aiming to enhance its cell therapy leadership. Following these positive outcomes, Repligen raised its full-year …

Replimune Is Locked in a Standoff With Regulators. Here Is What It Means for the Stock.

The biotech is seeking approval for its first commercial product in combination with Bristol Myers Squibb’s Opdivo. Continue Reading

ePlus Inc. (NASDAQ: PLUS) holder plans sale of 65 shares via Rockefeller Capital

An SEC Form 144 filing indicates that the Darren S Raiguel Trust plans to sell 65 common shares of ePlus Inc. (NASDAQ: PLUS) through Rockefeller Capital Management. The aggregate market value of this planned transaction is $6,041.50, with a proposed sale date of July …

Securities Fraud Investigation Into Replimune Group Inc. (REPL) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

The Law Offices of Frank R. Cruz has initiated a securities fraud investigation into Replimune Group Inc. (REPL) after the FDA deemed the company's mid-stage study for its skin cancer drug RP1 "not interpretable." This FDA assessment caused Replimune's stock price to fall by …

FDA staff reiterate concerns about Replimune skin cancer treatment

The FDA has again expressed concerns regarding Replimune's investigational skin cancer treatment, RP1, ahead of an advisory committee meeting. Regulators cite insufficient data to support approval, specifically questioning the reliance on a single-arm trial that combines RP1 with Opdivo in patients who have failed …

Form 144 EPLUS INC For: 28 July By Investing.com

This article announces the filing of Form 144 for EPLUS INC on July 28. It also includes a standard disclaimer from Investing.com about the risks associated with trading in financial instruments and cryptocurrencies. The disclaimer warns that data may not be real-time or accurate …

Investigation launched into Replimune after FDA doubts RP1 therapy data, shares drop 30%.

Johnson Fistel, PLLP has launched an investigation into Replimune Group, Inc. following a 30% drop in its share price. This decline occurred after the FDA released briefing documents that questioned the efficacy data for Replimune's RP1 therapy when combined with nivolumab, citing insufficient evidence …

Replimune Group, Inc. (REPL) Investors Who Suffered Losses

Johnson Fistel, PLLP is investigating Replimune Group, Inc. (NASDAQ: REPL) after its shares fell approximately 30% following the FDA's release of briefing documents raising concerns about Replimune’s investigational RP1 therapy. The FDA staff concluded that the IGNYTE trial was not adequate and well-controlled, and …

REPL Stock Clocks Worst Day In Over 3 Months — New FDA Documents Leave Wall Street Awaiting Another Rejection For Cancer Drug

Shares of Replimune Group Inc (REPL) dropped 38% after the FDA released documents questioning the approval of its experimental cancer drug RP1. This marks the company's third attempt for accelerated approval in combination with nivolumab for advanced melanoma, following prior rejections due to an …

Repligen Corporation Stock 12‑Month Price Target Raised to $180.33, Implies 38% Upside

Analysts have raised Repligen Corporation's average 12-month price target to $180.33, up from $176.28. This new target suggests a potential upside of approximately 38% from its July 27 closing price. The consensus rating for RGEN remains a "Buy" among 22 analysts.

ePlus will release results after close, webcast starts at 4:30 p.m.

ePlus (NASDAQ: PLUS) announced it will release its first quarter fiscal year 2027 earnings for the three months ended June 30, 2026, after market close on August 4, 2026. A conference call and audio webcast with management will follow at 4:30 p.m. ET. Investors …

EPlus Announces First Quarter Fiscal Year 2027 Earnings Release Date and Conference Call

ePlus inc. (NASDAQ NGS: PLUS) has announced that it will release its first quarter fiscal year 2027 earnings on August 4, 2026, after the market closes. The company will also host a conference call and audio webcast at 4:30 p.m. ET on the same …

Repligen (RGEN) Held An M&A Call With BioLife Solutions.

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Repligen (NasdaqGS:RGEN) and BioLife Solutions recently held a merger and acquisition call. The discussion focused on potential combinations or partnerships in bioprocessing and cell and gene therapy …

Replimune Lead Drug Trial Data Deemed 'Not Interpretable' by FDA Staff

The FDA has deemed Replimune's mid-stage study data for its lead drug RP1 as "not interpretable," challenging the company's application for accelerated approval in combination with Bristol-Myers Squibb Co.'s Opdivo for advanced melanoma. Concerns were raised regarding the efficacy assessment from the single-arm IGNYTE …

Repligen Stock Rises As $1.5B BioLife Deal Targets EPS Boost

Repligen Corporation's stock rose significantly after announcing a $1.5 billion cash-and-stock deal to acquire BioLife Solutions. This acquisition aims to boost Repligen's EPS, adjusted margins, and revenue growth by expanding its bioprocessing footprint into the rapidly growing cell and gene therapy market with BioLife's …

Repligen (NASDAQ:RGEN) Rallies as Quality Stock Delivers Earnings Beat

Repligen (NASDAQ:RGEN) reported a significant earnings beat for Q2 2026, with non-GAAP EPS of $0.54 against an analyst consensus of $0.46, despite revenue being marginally below expectations. The stock surged over 75% in pre-market trading, recouping recent losses, as investors prioritized profitability improvements. The …

Replimune Stock Slides As Losses Deepen And Legal Risks Rise

Replimune Group Inc. (REPL) stock slid over 21% following clinical setbacks, deeper-than-expected losses, and a newly launched legal probe into alleged misstatements regarding its IGNYTE trial and RP1 program. The company reported a net loss of $3.38 per share, exceeding estimates, and faces a …

US FDA staff cast doubt on Replimune cancer drug’s benefit; shares slide

FDA staff reviewers have expressed doubts about the benefits of Replimune's skin cancer drug, RP1, citing flaws in the trial design that make it difficult to determine its effectiveness when used in combination with Bristol Myers Squibb's Opdivo. The FDA had previously declined approval …

Repligen Corp (RGEN) Q2 2026 Earnings Call Transcript

Repligen Corp announced strong Q2 2026 earnings, with 12% reported growth and 13% organic growth, leading to a raised full-year guidance for organic revenue and adjusted EPS. The company saw robust performance in proteins and analytics, with significant growth in APAC and emerging biotech. …